Compass Therapeutics' (CMPX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price target on the stock.

Several other equities research analysts also recently weighed in on CMPX. Guggenheim started coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They set a "buy" rating and a $12.00 target price for the company. Jefferies Financial Group increased their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Piper Sandler assumed coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price target for the company. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Compass Therapeutics has an average rating of "Buy" and an average target price of $13.38.

Compass Therapeutics Trading Down 9.0 %

Shares of NASDAQ CMPX traded down $0.15 during mid-day trading on Tuesday, reaching $1.46. The company had a trading volume of 1,726,053 shares, compared to its average volume of 814,985. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08. The stock has a market cap of $201.89 million, a P/E ratio of -3.95 and a beta of 1.19. The firm has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, equities analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at about $35,000. Tang Capital Management LLC increased its holdings in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after buying an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC increased its holdings in Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after buying an additional 9,451 shares in the last quarter. MPM Bioimpact LLC lifted its position in shares of Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after acquiring an additional 2,926,002 shares during the period. Finally, Enavate Sciences GP LLC purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth approximately $11,293,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.